Potential medical applicability of N-β-Ala and N-His dipeptidomimetics against breast cancer: short in vitro and in silico screening
Klaudia Chmielewska, Justyna Budka, Katarzyna Kozłowska-Tylingo, Iwona Inkielewicz-Stepniak, Krystyna Dzierzbicka · 2026
Read Potential medical applicability of N-β-Ala and N-His dipeptidomimetics against breast cancer: short in vitro and in silico screening by Klaudia Chmielewska, Justyna Budka, Katarzyna Kozłowska-Tylingo, Iwona Inkielewicz-Stepniak, Krystyna Dzierzbicka (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13369175.txt.
Description
Short peptide-like molecules, tuned to survive the body, might one day carry cancer drugs to their targets. Klaudia Chmielewska and co-authors screen eighteen such dipeptidomimetics in a 2026 study, pairing quick lab tests with heavy computer modeling.
The compounds dress two building blocks, beta-alanine and histidine, in protective chemical clothing. Two stood out, one from each family, showing early signs of selectivity in the breast cancer tests. The authors are candid about scope: this is a short first screen, not a drug claim. Its value is the detailed theoretical data, binding and behavior predictions, published for teams hunting new conjugation partners. They also argue the pairing of cheap computation with small experiments should be standard practice before anyone funds the expensive biology.
Catalog record
| CREATOR | Klaudia Chmielewska, Justyna Budka, Katarzyna Kozłowska-Tylingo, Iwona Inkielewicz-Stepniak, Krystyna Dzierzbicka |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |